Global NTM Infections Pipeline Poised for Growth as Breakthrough Therapies Advance Toward Late-Stage Development, states DelveInsight

Prominent Nontuberculous Mycobacterial (NTM) Infections emerging therapies include ALIS, Antimycobacterial regimen, ...
MPR

MannKind Ends Trial of Nebulized Clofazimine for NTM Lung Disease

A phase 3 trial evaluating a nebulized clofazimine inhalation suspension (MNKD-101) for the treatment of refractory nontuberculous mycobacterial (NTM) ...

MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease

MannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation suspension for ...

Emerging infections you should know about and how to prevent them

The rise of infections caused by Mgen, C. auris, treatment-resistant E. coli, and more could become future public-health threats, experts say.
emjreviews.com

Why Stubborn Lung Infections Persist Despite Therapy

STUBBORN lung infection can evolve within patients and develop traits that help it persist over time. Chronic pulmonary disease caused by Mycobacterium avium complex remains difficult to manage and ...